Pharmaceuticals 2010, 3(7), 2213-2224; doi:10.3390/ph3072213
Review

High-Dose Ibuprofen in Cystic Fibrosis

1, 2,* email and 2email
Received: 23 June 2010; in revised form: 6 July 2010 / Accepted: 8 July 2010 / Published: 13 July 2010
(This article belongs to the collection Non-Steroidal Anti-Inflammatory Drugs)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Cystic Fibrosis (CF) is the most common lethal genetic disorder in North America and Europe. Most patients succumb to progressive lung disease characterized by an exaggerated neutrophilic inflammation. In animal models of chronic infection, high-dose ibuprofen was demonstrated to reduce inflammation without hindering bacterial clearance. This led to two clinical trials, which demonstrated a benefit in slowing the progression of lung disease in CF. However, concerns about potential adverse effects have limited the use of high-dose ibuprofen in CF patients. There are a variety of potential mechanisms to account for the observed clinical benefit. A better understanding of these mechanisms could potentially lead to more targeted and better-tolerated anti-inflammatory therapies.
Keywords: ibuprofen; interleukin-8; neutrophils; cystic fibrosis; CFTR
PDF Full-text Download PDF Full-Text [123 KB, uploaded 13 July 2010 13:48 CEST]

Export to BibTeX |
EndNote


MDPI and ACS Style

Lands, L.C.; Dauletbaev, N. High-Dose Ibuprofen in Cystic Fibrosis. Pharmaceuticals 2010, 3, 2213-2224.

AMA Style

Lands LC, Dauletbaev N. High-Dose Ibuprofen in Cystic Fibrosis. Pharmaceuticals. 2010; 3(7):2213-2224.

Chicago/Turabian Style

Lands, Larry C.; Dauletbaev, Nurlan. 2010. "High-Dose Ibuprofen in Cystic Fibrosis." Pharmaceuticals 3, no. 7: 2213-2224.

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert